Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22074666 | 0.89 | HDAC6 (0.49) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL19746136 | 0.83 | HDAC6 (0.57) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21407367 | 0.83 | HDAC6 (0.54) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL20529791 | 0.83 | HDAC6 (0.55) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL22074638 | 0.83 | HDAC6 (0.59) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL20689829 | 0.83 | HDAC6 (0.64) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL22074674 | 0.82 | HDAC6 (0.61) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL19747008 | 0.82 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL24168687 | 0.81 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL22074667 | 0.80 | HDAC6 (0.55) | HDAC6HDAC1HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447481-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-09-20 | — | — | US | disclosed |
| US-20200190076-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-06-18 | — | — | US | disclosed |
| US-20200190076-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447481-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG2 | HDAC6 611/4885HDAC1 584/4885HDAC8 1774/4885 |
| US-20200190076-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG2 | HDAC6 611/4885HDAC1 584/4885HDAC8 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.